Company Filing History:
Years Active: 1990
Title: Innovator Kiyomi Sunaga and Her Contributions in Monoclonal Antibody Development
Introduction
Kiyomi Sunaga, an esteemed inventor based in Kawasaki, Japan, has made significant strides in the field of biotechnology. She is known for her innovative work involving monoclonal antibodies, which play a pivotal role in cancer diagnosis. With one patent to her name, Sunaga's contributions are recognized in the scientific community and beyond.
Latest Patents
Sunaga's patent is a groundbreaking development titled "Monoclonal antibody and method for preparation of hybridoma producing." This patent details a monoclonal antibody that specifically recognizes an O-acylsialic acid containing sugar chain. The invention also describes a method for preparing a hybridoma capable of producing this monoclonal antibody. This process uses an autoimmune disease animal as the immunization subject and employs a substance containing the sugar chain adsorbed on Salmonella minnesota bacteria as the immunogen. The monoclonal antibody developed in this patent is particularly valuable for diagnosing cancer, as it targets antigens related to human malignancies.
Career Highlights
Kiyomi Sunaga has established her career at Konica Corporation, where she continues to contribute to advancements in medical and biotechnological research. Her innovative methods and insights into hybridoma technology highlight her role as a leader in her field.
Collaborations
Throughout her career, Sunaga has collaborated with notable colleagues, including Masahiko Yamasaki and Yoshitaka Nagai. These collaborations have facilitated the sharing of ideas and expertise, furthering the impact of their collective work within the biotechnology sector.
Conclusion
Kiyomi Sunaga's work on monoclonal antibodies exemplifies the profound impact that individual inventors can have on science and medicine. Her innovative approach not only advances understanding in her field but also provides essential tools for cancer diagnosis. As she continues her work at Konica Corporation, her contributions will undoubtedly inspire future innovations in biotechnology.